High-power helium-neon laser irradiation inhibits the growth of traumatic scars in vitro and in vivo.
This study explored the inhibitory effect of the high-power helium-neon (He-Ne) laser on the growth of scars post trauma. For the in vitro study, human wound fibroblasts were exposed to the high-power He-Ne laser for 30 min, once per day with different power densities (10, 50, 100, and 150 mW/cm(2)). After 3 days of repeated irradiation with the He-Ne laser, fibroblast proliferation and collagen synthesis were evaluated. For in vivo evaluation, a wounded animal model of hypertrophic scar formation was established. At postoperative day 21, the high-power He-Ne laser irradiation (output power 120 mW, 6 mm in diameter, 30 min each session, every other day) was performed on 20 scars. At postoperative day 35, the hydroxyproline content, apoptosis rate, PCNA protein expression and FADD mRNA level were assessed. The in vitro study showed that the irradiation group that received the power densities of 100 and 150 mW/cm(2) showed decreases in the cell proliferation index, increases in the percentage of cells in the G0/G1 phase, and decreases in collagen synthesis and type I procollagen gene expression. In the in vivo animal studies, regions exposed to He-Ne irradiation showed a significant decrease in scar thickness as well as decreases in hydroxyproline levels and PCNA protein expression. Results from the in vitro and in vivo studies suggest that repeated irradiation with a He-Ne laser at certain power densities inhibits fibroblast proliferation and collagen synthesis, thereby inhibits the growth of hypertrophic scars.
Department of Rehabilitation Medicine, Institute of Field Surgery, Daping Hospital, Third Military Medical University, No.10, Changjiangzhilu, Yuzhong District, Chongqing, 400042, China. shubin1017@163.com
Bin
B
Shu
Guo-Xin
GX
Ni
Lian-Yang
LY
Zhang
Xiang-Ping
XP
Li
Wan-Ling
WL
Jiang
Li-Qun
LQ
Zhang
D000293:Adolescent; D000328:Adult; D000818:Animals; D049109:Cell Proliferation; D002478:Cells, Cultured; D002921:Cicatrix / Q000378:metabolism / Q000473:pathology / Q000601:surgery*; D017439:Cicatrix, Hypertrophic / Q000378:metabolism / Q000473:pathology / Q000601:surgery; D003094:Collagen / Q000096:biosynthesis; D024042:Collagen Type I / Q000235:genetics; D053200:Fas-Associated Death Domain Protein / Q000235:genetics; D005260:Female; D005347:Fibroblasts / Q000378:metabolism / Q000473:pathology; D006801:Humans; D006909:Hydroxyproline / Q000378:metabolism; D054020:Lasers, Gas / Q000627:therapeutic use*; D008297:Male; D018809:Proliferating Cell Nuclear Antigen / Q000378:metabolism; D012333:RNA, Messenger / Q000235:genetics / Q000378:metabolism; D011817:Rabbits; D055815:Young Adult
D024042:Collagen Type I; D053200:Fas-Associated Death Domain Protein; D018809:Proliferating Cell Nuclear Antigen; D012333:RNA, Messenger; D003094:Collagen; D006909:Hydroxyproline